Are interleukin 17 and interleukin 23 inhibitors associated with malignancies? - Insights from an international population-based study.
Khalaf KridinMariam AbdelghaffarNoor MruwatRalf J LudwigDiamant ThaçiPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
IL-17i and IL-23i are associated with decreased risk of several malignancies. These findings should be considered prior to the prescription of biologics. This article is protected by copyright. All rights reserved.
Keyphrases